· Investigational New Drug application approved by the FDA for COVID-19 candidate vaccine, allowing BAT to progress into a Phase I clinical trial in adult volunteers
· Vaccine candidate created using innovative plant-based technology
· Vaccines manufactured using BAT’s vaccine platform have the potential to be stable at room temperature which could offer significant advantages
· Study demonstrates BAT’s commitment to delivering science and innovation that build A Better Tomorrow
BAT’s US Bio-tech arm, Kentucky BioProcessing (KBP) today announced plans to commence a Phase I, first-time-in-human study of its COVID-19 vaccine candidate following approval of its Investigational New Drug application by the U.S. Food and Drug Administration (FDA). Enrolment for the study is expected to begin shortly.The COVID-19 vaccine candidate (KBP-COVID-19; NCT04473690) will become one of a number of potential vaccines to have progressed beyond pre-clinical testing. The study is designed to enroll a total of 180 healthy volunteers who will be divided into two age cohorts, age 18-49 and age 50-70. Each group will then be subdivided into low and high dose treatment groups (N~45) and randomised 2:1 to receive either the low dose (15 μg KBP-COVID-19 vaccine + 0.5 mg adjuvant) or placebo, or high dose (45 μg KBP-COVID-19 vaccine + 0.5 mg adjuvant) or placebo. Results from the study are expected mid-2021 and, if positive, would allow for continued progress into a Phase 2 study, subject to regulatory approval.The candidate vaccine has been developed using KBP’s innovative fast-growing plant-based technology. This unique approach has a number of possible advantages, including the rapid production of the vaccine’s active ingredients in around 6-weeks, compared to several months using conventional methods. The candidate vaccine also has the potential to be stable at room temperature, which could be a significant advantage for healthcare systems and public health networks worldwide. If successful, the speed of production of the active ingredients has the potential to reduce the time between identifying new viruses and strains, and vaccine development and deployment to those who need it.KBP is conducting and recently completed enrolment for a Phase I clinical study of its quadrivalent (four-strain) influenza vaccine candidate (KBP-V001; NCT04439695), which uses the same nicotiana benthamiana plant-based technology platform.
“Moving into human trials with both our COVID-19 and seasonal flu vaccine candidates is a significant milestone and reflects our considerable efforts to accelerate the development of our emerging biologicals portfolio. It is our unique plant-based vaccine technology, which acts as a fast, efficient host for the production of antigens for a variety of diseases, that has enabled us to make this progress and respond to the urgent global need for safe and effective treatments and vaccines.Dr David O’Reilly, BAT’s Director of Scientific Research
With both vaccines reaching these important milestones, the science around tobacco plant-based vaccine development and the unique platform continue to gain momentum.
“This is part of our ongoing commitment to innovation and science, which are fundamental to our business. As a company committed to building A Better Tomorrow, we are proud to play our part in the global fight against this virus and – hopefully – we can contribute to the solution.”Beverley Spencer-Obatoyinbo, BAT Kenya’s Managing Director
CEO Africa is our flagship magazine/ Website under MELSAV Co. Ltd. with an in depth coverage of business, finance, corporate and general entrepreneurial matters, founded in 2010.
Its editorial policy is driven by quest to help CEOs and Managing Directors communicate their agenda and instill prudent management traits within their organizations. Since its inception eight years ago, CEO Africa remains Steady and focused as a business journal with vision to cover and circulate the whole continent.
CEO Africa Magazine is a full color, UV varnished custom size magazine published monthly with understanding of the emerging trends in entrepreneurship and businesses across the region. The company prints 3,000 copies per month for distribution.
Our driving force is service excellence; the only means by which we recognize CEO Africa Brand.